⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
ERAS News
Erasca, Inc. Common Stock
Erasca Announces Positive Preliminary Phase 1 Dose Escalation Data for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid Tumors
globenewswire.com
ERAS
Form 8-K
sec.gov
ERAS
Erasca to Host Conference Call and Webcast to Discuss Preliminary Phase 1 Dose Escalation Data for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015
globenewswire.com
ERAS
Form 8-K
sec.gov
ERAS
Erase.com Named One of the 2026 Best Workplaces(TM) in Canada
accessnewswire.com
ERAS
Actuate Therapeutics: Poised for Potential $200M+ Pediatric Priority Review Vouchers and Transformative Combinations in RAS-Driven Cancers
accessnewswire.com
ACTU
RVMD
ERAS
Form 8-K
sec.gov
ERAS
Erasca Reports Fourth Quarter and Full Year 2025 Business Updates and Financial Results
globenewswire.com
ERAS
Erasca Exercises Option to Secure Worldwide Rights for ERAS-0015 Pan-RAS Molecular Glue to Include China, Hong Kong, and Macau
globenewswire.com
ERAS
Erasca and Tango Therapeutics Enter into Clinical Collaboration to Evaluate Combination of ERAS-0015 and Vopimetostat
globenewswire.com
TNGX
ERAS